Search Results - andrew+zimmerman

1 Results Sort By:
Hydroxyurea in Autism
C11387: Hydroxyurea for the Treatment of AutismNovelty: This technology employs hydroxyurea (HU), a common treatment for sickle cell disease, to reduce core symptoms, like social responsiveness, in patients of all ages with autism.Value Proposition: Currently, the only available drugs for the treatment of autism are symptomatic. These drugs aim to...
Published: 7/4/2024   |   Inventor(s): Kirby Smith, Andrew Zimmerman
Keywords(s): Antagonists/Inhibitors, Autism, CNS and Neurological Disorders, Disease Indication, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Psychiatry > Autism, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Psychiatry, Technology Classifications > Therapeutic Modalities
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum